NVAX - Novavax, Inc.
IEX Last Trade
12.37
0.970 7.842%
Share volume: 9,695,440
Last Updated: Fri 30 Aug 2024 09:59:59 PM CEST
Research and Development in Biotechnology (except Nanobiotechnology):
0.21%
PREVIOUS CLOSE
CHG
CHG%
$11.40
0.97
8.51%
View ratios
| Fiscal Date | 2022-03-31 | 2022-06-30 | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 | |
|---|---|---|---|---|---|---|---|---|---|
| Fiscal Quarter | Q1 2022 | Q2 2022 | Q3 2022 | Q4 2022 | Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | |
| Report Date | 2022-05-10 | 2022-08-09 | 2022-11-09 | 2023-02-28 | 2023-05-09 | 2023-08-08 | 2023-11-09 | 2024-02-28 | |
| Assets | |||||||||
| Total Assets | 2.835 B | 2.623 B | 2.267 B | 2.259 B | 1.543 B | 1.685 B | 1.657 B | 1.797 B | |
| Current Assets | 2.347 B | 2.136 B | 1.760 B | 1.703 B | 971.028 M | 1.128 B | 1.007 B | 1.144 B | |
| Inventories | 106.648 M | 256.301 M | 82.432 M | 36.683 M | 34.185 M | 23.488 M | 69.592 M | 41.696 M | |
| Other Current Assets | 180.155 M | 299.307 M | 274.522 M | 237.147 M | 188.714 M | 192.903 M | 152.018 M | 226.023 M | |
| Short Term Investments | 180.155 M | 299.307 M | 274.522 M | 237.147 M | 188.714 M | 192.903 M | 152.018 M | 226.023 M | |
| Total Receivables | 478.156 M | 194.533 M | 111.645 M | 82.375 M | 112.849 M | 394.890 M | 123.657 M | 297.240 M | |
| Current Cash | 1.571 B | 1.376 B | 1.281 B | 1.337 B | 624.950 M | 505.912 M | 651.104 M | 568.505 M | |
| Total Non-current Assets | 487.470 M | 486.991 M | 507.472 M | 555.288 M | 571.671 M | 557.494 M | 650.393 M | 653.602 M | |
| Property Plant Equipment | 247.213 M | 254.526 M | 255.532 M | 294.247 M | 307.414 M | 299.955 M | 300.982 M | 305.771 M | |
| Other Assets | 18.614 M | 19.195 M | 17.406 M | 28.469 M | 30.507 M | 33.434 M | 34.890 M | 35.159 M | |
| Intangible Assets | 4.535 M | 4.033 M | 8.456 M | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Goodwill | 130.756 M | 123.467 M | 117.535 M | 126.331 M | 129.827 M | 128.366 M | 123.780 M | 127.454 M | |
| Liabilities and shareholders’ equity | |||||||||
| Total Liabilities and shareholders’ equity | 2.835 B | 2.623 B | 2.267 B | 2.259 B | 1.543 B | 1.685 B | 1.657 B | 1.797 B | |
| Total liabilities | 2.770 B | 3.040 B | 2.833 B | 2.893 B | 2.438 B | 2.440 B | 2.336 B | 2.514 B | |
| Total current liabilities | 2.261 B | 2.156 B | 1.668 B | 2.460 B | 1.919 B | 1.596 B | 1.469 B | 1.635 B | |
| Accounts Payable | 135.128 M | 386.488 M | 144.997 M | 216.517 M | 124.801 M | 87.246 M | 101.914 M | 132.610 M | |
| Other liabilities | 508.546 M | 883.704 M | 1.134 B | 235.109 M | 321.573 M | 645.320 M | 646.138 M | 655.340 M | |
| Current long term debt | 440.498 M | 448.429 M | 406.620 M | 352.077 M | 1.205 M | 953.000 K | 1.332 M | 5.142 M | |
| Long term debt | 0.000 | 0.000 | 31.474 M | 197.704 M | 197.850 M | 197.992 M | 220.779 M | 223.939 M | |
| Other liabilities | 508.546 M | 883.704 M | 1.134 B | 235.109 M | 321.573 M | 645.320 M | 646.138 M | 655.340 M | |
| Minority interest | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Total Shareholder equity | 65.324 M | -416.950 M | -565.985 M | -634.078 M | -895.582 M | -754.519 M | -678.350 M | -716.927 M | |
| Common stock | 76.457 M | 78.143 M | 78.274 M | 79.858 M | 86.158 M | 89.362 M | 103.429 M | 124.123 M | |
| Retained earnings | -3.415 B | -3.925 B | -4.094 B | -4.276 B | -4.570 B | -4.512 B | -4.643 B | -4.821 B |